We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Thromboelastometry Predicts Thromboembolic Events in COVID-19 Patients

By LabMedica International staff writers
Posted on 05 Jul 2022
Print article
Image: ROTEM delta analysis helps optimize patient treatment and monitor results. Four channels and a comprehensive reagent portfolio aid in the evaluation of coagulopathies (Photo courtesy of Werfen)
Image: ROTEM delta analysis helps optimize patient treatment and monitor results. Four channels and a comprehensive reagent portfolio aid in the evaluation of coagulopathies (Photo courtesy of Werfen)

In addition to severe pulmonary and renal injury, abnormality of hemostasis is recognized as a contributing factor to the severity of the COVID-19. Thromboembolic complications were diagnosed in 31% of patients with COVID-19 infection admitted to an intensive care unit, despite anticoagulation therapy.

Assessment of hemostasis with traditional plasma coagulation tests (e.g., prothrombin time, activated thromboplastin time) is often not helpful because they evaluate only the initial phase of clot formation and frequently do not demonstrate significant abnormality. Viscoelastic tests (e.g., thromboelastography (TEG), rotational thromboelastometry (ROTEM), or ClotPro) were developed to assess in real time all stages (dynamic) of clot formation and fibrinolysis using whole blood samples.

Clinical Scientists at the Warren Alpert Medical School of Brown University (Providence, RI, USA) and their colleagues carried out a prospective cohort study that included 25 patients and inclusion criteria were a positive PCR COVID-19 test result and respiratory insufficiency requiring supplemental oxygen. The primary outcome was defined as an unfavorable course of the disease if a patient: (1) developed a thromboembolic event while receiving anticoagulation prophylaxis, (2) had prolonged ICU stay, or (3) died.

Rotational thromboelastometry was performed by trained personnel using a ROTEM delta device (TEM Innovations GmbH, Bedford, MA, USA). The following ROTEM tests were performed: (1) EXTEM assay consisting of recombinant tissue factor and Polybrene (heparin inhibitor) added to re-calcified whole blood to activate the extrinsic pathway and initiate coagulation, (2) In the FIBTEM assay, the contribution of platelets to clot formation is eliminated allowing to assess fibrinogen contribution (functional fibrinogen) to hemostasis. It is performed by an addition of recombinant tissue factor, polybrene and platelet inhibitor cytochalasin D added to the whole blood sample to activate the extrinsic pathway while suppressing platelets.

The investigators reported that there were 16 patients with an unfavorable course of the disease. Compared to the nine patients in the favorable course group, patients with an unfavorable course had a lower platelet count, median difference of 154 × 109/L (95% CI, 26 to 223 × 109/L), and lower clot firmness parameters in EXTEM assay: amplitude at 20 minutes (A20), median difference of 7, maximum clot firmness (MCF), median difference of 6 and area under the curve (AUC) with a median difference of 671. They also demonstrated suppression of fibrinolysis: higher lysis index 60, median difference of − 3. Results of functional fibrinogen (FIBTEM) assay were similar between the groups.

The authors concluded that the platelet count and the results of EXTEM assay, but not FIBTEM assay, were associated with the difference in clinical outcome among patients with COVID-19 infection and hypoxemia. The study was published on June 28, 2022 in the Journal of Blood Medicine.

Related Links:
Warren Alpert Medical School of Brown University 
TEM Innovations GmbH

New
Gold Supplier
Automated Chemiluminescent Analyzer
BIO-FLASH
New
Silver Supplier
Point-of-Care MDx System
STANDARD M10
New
Silver Supplier
Hemoglobin Testing System
VARIANT II TURBO
New
Legionella Pneumophila Assay
C4Legio LFA

Print article

Channels

Molecular Diagnostics

view channel
Image: The new multiplex QIAstat-Dx Viral Vesicular Panel is designed to support research and surveillance efforts (Photo courtesy of QIAGEN)

First Syndromic Test Differentiates Between Monkeypox and Five Pathogens with Similar Symptoms

A new syndromic test differentiates between monkeypox and five other pathogens which cause similar symptoms. This first-ever test detects the two known forms of monkeypox virus (the so-called West African... Read more

Industry

view channel
Image: The Accelerate Arc Module & BC kit is registered as an IVD (Photo courtesy of Accelerate Diagnostics)

BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.